ArticleBJUI compass2025
Precision in kidney-sparing surgery: Robot-assisted ureterectomy with novel Black Eye™ Ink.
Article in BJUI compass, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-analysis of perioperative and renal functional outcomes of Robot-Assisted Partial Ureterectomy (RASU) versus complete Nephroureterectomy (RARNU) for upper tract urothelial tumors.Journal of robotic surgery · 2026Pooled it
- Robotic segmental ureterectomy for upper tract urothelial carcinoma: comparable short-term oncological outcomes and improved postoperative recovery compared to open approach.World journal of surgical oncology · 2026Article
- Precision in kidney-sparing surgery: Robot-assisted ureterectomy with novel Black Eye™ Ink.BJUI compass · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the feasibility, oncological efficacy and safety of robotic segmental ureterectomy (SU) for treating patients with localised upper tract urothelial carcinoma (UTUC). A key aspect of this research involves utilising Black Eye™ Endoscopic Marker Ink to delineate the boundary of the tumour in the ureter, helping to ensure precise surgical intervention and reducing the risk of positive surgical margin. Patients and Methods: In a prospective non-randomised trial from January 2018 to December 2022, patients with localised UTUC confirmed by CT-urography were enrolled. A Multidisciplinary Team assessed patients for suitability for kidney-sparing surgery (KSS) with SU, marked by endoscopic Black Eye™ Endoscopic Marker Ink. Black Eye Endoscopic Marker Ink marking aimed to enhance surgical precision by delineating clear resection margins. The primary endpoints were the feasibility of the technique, local and bladder recurrence rates and surgical outcomes. Propensity score matching was used for a balanced comparison to the standard treatment Radical Nephroureterectomy (RNU). Results: Thirty patients underwent SU, in the period of study with only one local recurrence reported with a median follow-up time of 35 months. SU was associated with a significantly shorter operative time (41 minutes less on average, Conclusion: SU with Black Eye™ Endoscopic Marker Ink marking is a viable KSS technique that offers a safe and effective alternative to RNU for patients with a single tumour, no longer than 30 mm and of low grade. This novel approach is promising in lowering the risk of positive margins, ensuring cancer control and preserving renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.